Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 50 pages | ID: VDBF48B692F6EN
VPAResearch

Abstracts

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline report- 2020 is an annual R&D review of Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline candidates. The report presents the current status of all major Vancomycin Resistant Staphylococcus aureus (VRSA) Infections therapeutic compounds. Detailed insights into Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline development, current status, companies, drug profiles and Vancomycin Resistant Staphylococcus aureus (VRSA) Infections preclinical and clinical trials are included.

2020 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Market Insights
Vancomycin Resistant Staphylococcus aureus (VRSA) Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Vancomycin Resistant Staphylococcus aureus (VRSA) Infections therapies, pipeline by phase and others are included.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Therapeutic Drug candidates
Both active and inactive Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline drug candidates are included in the report

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Clinical Trials and preclinical Studies
Vancomycin Resistant Staphylococcus aureus (VRSA) Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline market developments
Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline companies in active development
The report analyzes Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline of the below companies-

Century Therapeutics Inc, CrystalGenomics Inc, Debiopharm International SA, Destiny Pharma Ltd , iNtRON Biotechnology Inc, Therapeutic Systems Research Laboratories Inc, Wockhardt Ltd

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
7 Companies investing in Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Disease Overview
1.2 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug Pipeline Snapshot, 2020
  1.2.1 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Phase
  1.2.2 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Company
  1.2.3 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Route of Administration

2. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS COMPANY WISE PIPELINE DETAILS

Century Therapeutics Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
CrystalGenomics Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Debiopharm International SA Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Destiny Pharma Ltd Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
iNtRON Biotechnology Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Therapeutic Systems Research Laboratories Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Wockhardt Ltd Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts